No abstract

No abstract

The amount of TGF-beta contained in human whey was studied by the colony formation of NRK47F cells. It was noted that a factor inducing colony formation did exist in human whey, and its action was neutralized when anti-TGF-beta antibodies were introduced. This suggests that TGF-beta does exist in human whey. In colostrum, the total amount of TGF-beta was 1365.7 +/- 242.9 ng/ml, of which the active form comprised 728.1 +/- 248.7 ng/ml (n = 21). In late milk, the total TGF-beta was 952.5 +/- 212.6 ng/ml, with an active form of 178.7 +/- 157.3 ng/ml. Thus human milk contains a large amount of active TGF-beta. Furthermore, it was revealed by the reverse transcriptase polymerase chain reaction that mRNAs coding TGF-beta 1 and TGF-beta 2 exist in human milk cells. These results suggest that both TGF-beta 1 and TGF-beta 2 exist in human milk.

Antiviral activities of a recombinant feline interferon (rFeIFN) KT-80 were evaluated against feline enteropathogenic viruses in feline and canine cell lines. Sensitivity to antiviral activities of the rFeIFN varied with cell types; Felis catus whole fetus (fcwf-4) cells were more sensitive than Crandell feline kidney cells, but no sensitivity was found for Madin-Darby canine kidney cells when vesicular stomatitis virus was used as a challenge virus. Reductions were generally IFN dose-dependent and were more consistent when the cells were continuously treated with the rFeIFN than when they were pretreated only before viral challenge. Compared with each virus control culture of fcwf-4 cells, yields of rotavirus, feline panleukopenia virus (FPLV), feline calicivirus and feline infectious peritonitis coronavirus were reduced by ranges of 1.3 to < or = 3.1 log10, 0.6 to 1.6 log2, 0.8 to 3.7 log10 and 0.5 to 0.6 log10, respectively, in the cultures continuously treated with 10 to 10000 U of the rFeIFN. The yield reduction of FPLV was considered to be in part attributable to inhibition of cell growth by the rFeIFN supplemented in the medium.

No abstract